PRQR
ProQR Therapeutics NV
NASDAQ · Healthcare · Biotechnology · NL
$1.42
+3.66%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.37
From 52W high−42.04%
Volume538256.00
Market cap$200.41M
P/E (TTM)—
P/S (TTM)9.6x
Div yield—
Key dataNov 4, 2026
Open
$1.37
From 52W high
−42.04%
Volume
538256.00
Market cap
$200.41M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
43.8
MomentumView details →
1D Return
+3.66%
YTD Return
−30.69%
SummaryUpdated Jun 1, 2026
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a Dutch biopharmaceutical company founded in 2012 and headquartered in Leiden, the Netherlands. The company went public in September 2014 and specializes in developing RNA-based therapeutic treatments for rare genetic disorders. ProQR focuses primarily on inherited diseases that cause blindness and other serious genetic conditions, utilizing innovative RNA editing and antisense oligonucleotide technologies to address previously untreatable genetic mutations.
Similar companies
Latest newsMore news →
ProQR Therapeutics announced that it will present clinical and preclinical progress on AX-0810, AX-0811 and its Axiomer RNA editing platform at upcoming conferences.7d agoProQR Therapeutics dosed the first participant in the Phase 1 clinical trial of AX-0811 in healthy volunteers, marking the start of the study.56d ago